Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 12, 2008, Pages 1909-1916

  Sugino, Haruko ^a   Kumagai, Naoki ^b   Watanabe, Sakiko ^a   Toda, Kyoko ^b   Takeuchi, Osamu ^b   Tsunematsu, Satoshi ^b   Morinaga, Shojiroh ^b   Tsuchimoto, Kanji ^a,b  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO INSTITUTE HOSPITAL   (Japan)

Author keywords

Fibrosis; Methionine and choline deficient diet; Non alcoholic steatohepatitis; Polaprezinc; Zinc

Indexed keywords

POLAPREZINC; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; GENE EXPRESSION; LIPID PEROXIDATION; LIVER FIBROSIS; LIVER HISTOLOGY; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL;

EID: 57049135650     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05393.x     Document Type: Article

References (40)

1. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999 116 : 1413 9.
2. Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990 11 : 74 80.
3. Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002 123 : 134 40.
4. Hashimoto E, Yatsuji S, Kaneda H et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver diseases. Hepatol. Res. 2005 33 : 72 6.
5. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003 37 : 1202 19.
6. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2003 98 : 2485 90.
7. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am. J. Gastroenterol. 2001 96 : 2711 7.
8. Promrat K, Lutchman G, Uwaifo GI et al. A pilot study of pioglitazine treatment for nonalcoholic steatohepatitis. Hepatology 2004 39 : 188 96.
9. Bugianesi E, Gelentilcore E, Manini R et al. A randomized controlled trial of metoformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 2005 100 : 1082 90.
10. Agrawal S, Bonkovsky HL. Management of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2002 35 : 253 61.
11. Yokohama S, Yoneda M, Haneda M et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004 40 : 1222 5.
12. Bode JC, Hanisch P, Henning H, Koenig W, Richter FW, Bode C. Hepatic zinc content in patients with various stages of alcoholic liver diseases and in patients with chronic active and chronic persistent hepatitis. Hepatology 1988 8 : 1605 9.
13. Rocchi E, Borella P, Borghi A et al. Zinc and magnesium in liver cirrhosis. Eur. J. Clin. Invest. 1994 24 : 149 55.
14. Powell SR. The antioxidant properties of zinc. J. Nutr. 2000 130 : 1447S 54S.
15. Anttinen H, Olkarinen A, Puistola U, Pääkkö P, Ryhänen L. Prevention by zinc of rat lung collagen accumulation in carbon tetrachloride injury. Am. Rev. Respir. Dis. 1985 132 : 536 40.
16. Seltzer JL, Jeffrey JJ, Eisen AZ. Evidence for mammalian collagenases as zinc ion metalloenzyms. Biochim. Biophys. Acta 1977 485 : 179 87.
17. Giménez A, Parés A, Alié S et al. Fibrogenic and collagenolytic activity in carbon tetrachloride-treated rats: beneficial effects of zinc administration. J. Hepatol. 1994 21 : 292 8.
18. Dashti HM, Mathew TC, Jadaon MM, Ashkanani E. Zinc and liver cirrhosis: biochemical and histopathologic assessment. Nutrition 1997 13 : 206 12.
19. Yoshikawa T, Naito Y, Tanigawa T et al. Effect of zinc-carnosine chelate compound (Z-103), a novel antioxidant, on acute gastric mucosal injury induced by ischemia-reperfusion in rats. Free Radic. Res. Commun. 1991 14 : 289 96.
20. Yoshikawa T, Naito Y, Tanigawa T, Yoneta T, Kondo M. The antioxidant properties of a novel zinc-carnosine chelate compound, N-(3-aminopropionyl)-L- histidinato zinc. Biochem. Biophys. Acta 1991 1115 : 15 22.
21. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 2006 87 : 1 16.
22. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysis of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest. 2000 105 : 1067 75.
23. Ip E, Farrell GC, Robertson GR, Hall P, Kirsch R, Leclercq I. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003 38 : 123 32.
24. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959 37 : 911 7.
25. Danno H, Jincho Y, Budiyanto S, Furukawa Y, Kimura S. A simple enzymatic quantitative analysis of triglycerides in tissues. J. Nutr. Sci. Vitaminol. 1992 38 : 517 21.
26. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979 95 : 351 8.
27. George J, Pera N, Phung N, Leclercq I, Hou JY, Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J. Hepatol. 2003 39 : 756 64.
28. Browing JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J. Cin. Invest. 2004 114 : 147 52.
29. Yin M, Wheeler MD, Kono H et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999 117 : 942 52.
30. Koppe SWP, Sahai A, Malladi P, Whitington PF, Green RM. Pentoxyfylline attenuates steatohepatitis induced by the methionine choline deficient diet. J. Hepatol. 2004 41 : 592 8.
31. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996 111 : 1645 53.
32. Ludwig J, McGill DB, Lindor K. Metabolic liver diseases. Review: nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 1997 12 : 398 403.
33. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatisis in mice. Hepatology 2004 39 : 1286 96.
34. Arthur MJP, Fibrogenesis. II. Metalloproteinases and their inhibitors in liver fibrosis. Am. J. Gastrointest. Liver Physiol. 2000 279 : G245 G249.
35. Iredale JP, Benyon RC, Arthur MJP et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 1996 24 : 176 84.
36. Iredale JP, Benyon RC, Pickering J et al. Mechanisms of spontaneous resolution of rat liver fibrosis. J. Clin. Invest. 1998 102 : 538 49.
37. Takahashi M, Saito H, Higashimoto M, Hibi T. Possible inhibitory effect of oral zinc supplementation on hepatic fibrosis through downregulation of TIMP-1: a pilot study. Hepatol. Res. 2007 37 : 405 9.
38. Zhou Z, Wang L, Song Z, Saari JT, McClain CJ, Kang YJ. Zinc supplementation prevents alcoholic liver injury in mice through attenuation of oxidative stress. Am. J. Pathol. 2005 166 : 1681 90.
39. Boldyrev A, Bulygina E, Leinsoo T, Petrushanko I, Tsubone S, Abe H. Protection of neuronal cells against reactive oxygen specoes by carnosine and related compounds. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 2004 137 : 81 8.
40. Decker EA, Livisay SA, Zhou S. A re-evaluation of the antioxidant activity of purified carnosine. Biochemistry (Mosc) 2000 65 : 766 70.